Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53

Molecular Cancer Research

Volumn 13, Issue 3, 2015, Pages 493-501

  Quigley, David ^a,b,c   Silwal Pandit, Laxmi ^a,b   Dannenfelser, Ruth ^d,e   Langerød, Anita ^a,b   Vollan, Hans Kristian Moen ^a,b   Vaske, Charles ^f   Siegel, Josie Ursini ^g   Troyanskaya, Olga ^d,e   Chin, Suet Feung ^h   Caldas, Carlos ^h,i,j   Balmain, Allan ^c   Børresen Dale, Anne Lise ^a,b   Kristensen, Vessela ^a,b,k  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Faculty of Medicine   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Princeton University   (United States)

^e PRINCETON UNIVERSITY   (United States)

^f Five3 Genomics Inc ^*  (United States)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

^j Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^k AKERSHUS UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR; MESSENGER RNA; BIOLOGICAL MARKER; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ALGORITHM; ARTICLE; BASAL LIKE BREAST CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST TUMOR; CLUSTER ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE; FEMALE; GENETICS; HETEROZYGOSITY LOSS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928040878     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0387     Document Type: Article

References (41)

1. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
2. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
3. Silwal-Pandit L, Moen Vollan HK, Chin SF, Rueda OM, McKinney SE, Osako T, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 2014;20:3569-80.
4. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360:852-4.
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
7. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010;16:5222-32.
8. Enerly E, Steinfeld I, Kleivi K, Leivonen S-K, Aure MR, Russnes HG, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 2011;6:e16915.
9. Ronneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, et al. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011;5: 61-76.
10. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
11. Joshi H, Bhanot G, Borresen-Dale AL, Kristensen V. Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway. Br J Cancer 2012;107:1722-8.
12. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
13. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
14. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-83.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science 2011; 331:1565-70.
16. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40: 177-86.
17. Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet 1971;2:1282-3.
18. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-81.
19. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the Immunoscore in the classification of malignant tumours. J Pathol 2014;232:199-209.
20. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
21. Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 2010;10:604.
22. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-13.
23. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14: 5158-65.
24. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, et al. Tcell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009;11:R15.
25. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
26. Ali H, Provenzano E, Dawson S-J, Blows F, Liu B, Shah M, et al. Association between CD8 +T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 2014;25:1536-43.
27. Kristensen VN, Vaske CJ, Ursini-Siegel J, VanLoo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012;109:2802-7.
28. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch AG, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 2010;38:e17.
29. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107:16910-15.
30. R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
31. Anderson MJ, Ter Braak CJ. F. Permutation tests for multi-factorial analysis of variance. J Stat Comput Sim 2003;73:85-113.
32. Manly BFJ. Randomization, bootstrap, and Monte Carlo methods in biology. 3rd ed. Chapman & Hall/CRC; 2007.
33. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005;21:3448-9.
34. Yaari G, Bolen CR, Thakar J, Kleinstein SH. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. Nucleic Acids Res 2013;41:e170.
35. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4 (+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013;123:2873-92.
36. Ju W, Greene CS, Eichinger F, Nair V, Hodgin JB, Bitzer M, et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res 2013;23:1862-73.
37. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746-54.
38. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5.
39. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
40. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
41. Meslin F, Thiery J, Richon C, Jalil A, Chouaib S. Granzyme B-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells. J Biol Chem 2007;282:32991-9.